172
Participants
Start Date
May 10, 2021
Primary Completion Date
March 3, 2025
Study Completion Date
June 30, 2026
evorpacept
IV Q3W
pembrolizumab
IV Q3W
Cisplatin/Carboplatin; 5FU
IV Q3W
Amsterdam UMC, Locatie VUMC, Amsterdam
Grupo Hospital de Madrid (HM) - Hospital Universitario Madrid Sanchinarro - Cent, Madrid
Peter MacCallum Cancer Centre, Melbourne
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Royal Brisbane and Womens Hospital, Herston
Ashford Cancer Centre, Adelaide
Sir Charles Gairdner Hospital, Nedlands
Samsung Medical Center, Seoul
AZ Groeninge, Kortrijk
Universitair Medisch Centrum Groningen, Groningen
Memorial Sloan Kettering, New York
CHA University - Bundang CHA General Hospital (CHA Bundang Medical Center), Seongnam-si
Seoul National University, Bundang Hospital, Seongnam
University of Maryland Medical System, Baltimore
Gachon University (GCU) - Gil Medical Center (Gil Hospital), Incheon
Chungbuk National University Hospital, Cheongju-si
Hospital Universitario Severo Ochoa, Leganés
Hospital Regional Universitario de Malaga, Málaga
Hospital Universitario de Navarra, Pamplona
University of Miami, Sylvester Comprehensive Cancer Center, Miami
Moffitt Cancer Center, Tampa
Vanderbilt - Ingram Cancer Center, Nashville
University of Louisville, Louisville
Yeungnam University Medical Center, Daegu
The Ohio State University, Columbus
Rush University Medical Center, Chicago
Houston Methodist Cancer Center, Houston
Cedar Sinai Medical Center, Los Angeles
University of California San Diego, La Jolla
Hoag Hospital, Irvine
Oregon Health & Science University/ Knight Cancer Institute, Portland
National University Cancer Institute, Singapore
National Cancer Centre Singapore, Singapore
Cliniques Universitaires Saint-Luc, Brussels
Hospital Universitario La Paz, Madrid
The Catholic University of Korea - Eunpyeong St. Mary's Hospital, Seoul
Seoul National University Hospital (SNUH) - SMG-SNU Boramae Medical Center, Seoul
Hospital Universitari Dexeus, Barcelona
Institut Catala d Oncologia (ICO), Badalona
Institut Catala dOncologia, L'Hospitalet de Llobregat
The Royal Marsden Hospital - Surrey, London
University College London Hospital, London
The Royal Marsden Hospital- London, London
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
ALX Oncology Inc.
INDUSTRY